Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18121090 | 0.77 | LMNA (0.32) | LMNAFDPS | |
| SCHEMBL21764594 | 0.73 | — | — | |
| SCHEMBL23786550 | 0.73 | ALDH1A1 (0.41) | MMP2MMP8 | |
| SCHEMBL17749561 | 0.72 | SMPD1 (0.32) | LMNAFDPSGRM4 | |
| SCHEMBL332472 | 0.71 | — | — | |
| SCHEMBL243552 | 0.71 | LMNA (0.40) | LMNAFDPSGRM4 | |
| SCHEMBL27570533 | 0.71 | LMNA (0.40) | LMNAFDPSGRM4 | |
| SCHEMBL24667529 | 0.69 | EGLN1 (0.32) | LMNAMMP2MMP3MMP8 | |
| Ammonia Solution, Strong SCHEMBL1310966 | 0.69 | LMNA (0.38) | LMNAFDPS | |
| SCHEMBL5400918 | 0.69 | LMNA (0.38) | LMNAFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230099074-A1 | ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS | MERCK SHARP & DOHME LLC (US) | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099074-A1 | ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS | CD44, FCGR2A, TNF | LMNA 4569/4885FDPS 2589/4885GRM4 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.